Advanced search
Start date
Betweenand
Related content

Effect of p-mapa associated with block receptor type 1 angiotensin (AT1) in the Cancer of bladder non-muscle invasive treatment

Grant number: 13/11346-5
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Start date: November 01, 2013
End date: October 31, 2014
Field of knowledge:Health Sciences - Medicine - Surgery
Principal Investigator:Patrick Vianna Garcia
Grantee:Paloma Monteiro da Silva
Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

The high rates of non-muscle invasive bladder cancer (NMIBC) recurrence may be related to the low effects of these therapies on the mechanisms of tissue repair, angiogenesis, and Reactive Oxygen Species (ROS). Nowadays, the most effective therapy for NMIBC is the Bacillus Calmette-Guerin (BCG) immunotherapy associated with transurethral resection. However, BCG causes side effects of different intensities from irritative symptoms to serious systemic reaction, which contributes to treatment interruption besides increasing cancer index recurrence after treatment, up to 30%. Also, the multifaceted nature of the angiogenesis process in malignant tumors suggests that the combination of drugs with antiangiogenic agents that modulate antioxidant species may be more effective than therapies involving only a single agent. In this context, stands out the immunomodulator P-MAPA for its versatility and minimal cytotoxicity revealed by preliminary studies in vivo and in vitro opening a new perspective for combating some types of cancers, including bladder cancer (NMIBC). Furthermore, the association of antiangiogenic drugs (Losartan) and P-MAPA may be an alternative more effective than conventional therapies with regard to the recurrence of tumors in non-muscle invasive bladder tumors and their malignancy. The aim of this study is to characterize and compare the histopathological and molecular effects of the immunomodulator P-MAPA concomitant to use of losartan (receptor blocker type 1 angiotensin II - AT1) in the NMIBC treatment of induced rats, as well as establish possible mechanisms of action of these immunotherapies involving cellular repair pathways and angiogenesis. For NMIBC, 20 animals are going to be chemically induced with a dose of 1.5 mg/kg of N-methyl-N-nitrosourea (MNU) dissolved in 0.3 ml sodium citrate (1M pH 6.0) every 15 days (week 0, 2, 4, 6), a total of four doses. The other five animals that did not receive MNU will be considered as the control group (Group 1). Two weeks after the last dose of MNU, the animals will be examined by cystography to evaluate the occurrence of tumor and subsequently divided into 4 groups (5 animals per group): Group MNU (Cancer - Group 2): is going to receive an intravesical dose of 0.3 mL 0.9% saline solution for 6 consecutive weeks; Group MNU + LOSARTAN (Group 3): is going to receive an oral dose of 75 mg/kg Losartan dissolved in 0.2 mL of 0.9% saline once a day for 6 consecutive weeks to block angiogenesis; Group MNU + P-MAPA (Group 4): is going to receive an intravesical dose of 5 mg/kg P-MAPA dissolved in 0.3 mL of 0.9% saline for 6 consecutive weeks; Group MNU + P-MAPA + LOSARTAN (Group 5) is going to receive simultaneous treatment with Losartan and P-MAPA according to 3 and 4 groups. After 16 weeks of treatment, the animals will be euthanized and urinary bladders collected and subjected to histopathological analysis, immunohistochemistry, and Western Blotting.(AU)

News published in Agência FAPESP Newsletter about the scholarship:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)